Skip to main content

Jennifer Shiunroh Li

Beverly C. Morgan, M.D., Distinguished Professor of Pediatric Cardiology
Pediatrics, Cardiology
1927C Childrens Hlth Ctr, Box 3090, Durham, NC 27710
1927C Childrens Hlth Ctr, Box 3090, Durham, NC 27710

Featured Works


The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.

Journal article J Pediatr · August 2010 Featured Work OBJECTIVES: To determine the efficacy and safety of eplerenone therapy in children with hypertension. STUDY DESIGN: A total of 304 children age 4-16 years with systolic blood pressure (SBP) >or=95th percentile were randomized to low-dose (25 mg daily), mid ... Full text Link to item Cite

Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.

Journal article Clin Pharmacol Ther · June 2010 Featured Work The incidence of cough in children receiving antihypertension therapy with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) is unknown. We analyzed patient-level data from eight randomized trials for the treatment of ... Full text Link to item Cite

Antiplatelet therapy in pediatric cardiovascular patients.

Journal article Pediatr Cardiol · May 2010 Featured Work Platelets play a critical role in normal physiologic processes such as hemostasis, wound healing, inflammation, and innate immunity. However, they also play a role in the pathologic process of thrombosis. Although antiplatelet therapy is most commonly used ... Full text Link to item Cite

Major infection after pediatric cardiac surgery: a risk estimation model.

Journal article Ann Thorac Surg · March 2010 Featured Work BACKGROUND: In pediatric cardiac surgery, infection is a leading cause of morbidity and mortality. We created a model to predict risk of major infection in this population. METHODS: Using the Society of Thoracic Surgeons Congenital Heart Surgery Database, ... Full text Link to item Cite

Safety and transparency of pediatric drug trials.

Journal article Arch Pediatr Adolesc Med · December 2009 Featured Work OBJECTIVES: To quantify the frequency and type of new safety information arising from studies performed under the auspices of the Pediatric Exclusivity Program, to describe the dissemination of these findings in the peer-reviewed literature and compare thi ... Full text Link to item Cite

Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle.

Journal article Am Heart J · January 2009 Featured Work BACKGROUND: Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor grow ... Full text Link to item Cite

Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.

Journal article Pediatr Cardiol · November 2008 Featured Work BACKGROUND: Infantile Pompe disease (glycogen storage disease type 2) is a fatal disorder caused by deficiency of acid alpha-glucosidase. This deficiency results in glycogen accumulation in the lysosomes of many tissues including cardiac muscle. The diseas ... Full text Link to item Cite

Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease.

Journal article Genet Med · October 2008 Featured Work PURPOSE: Enzyme replacement therapy in infants with Pompe disease prolongs survival, decreases cardiomegaly, and improves muscle function. Because ectopy has been previously described in these patients, we sought to determine the prevalence and types of ar ... Full text Link to item Cite

The economic returns of pediatric clinical trials of antihypertensive drugs.

Journal article Am Heart J · October 2008 Featured Work BACKGROUND: Congress has authorized the United States Food and Drug Administration (FDA) to provide industry sponsors with a 6-month extension of drug marketing rights under the Pediatric Exclusivity Provision if FDA-requested pediatric drug trials are con ... Full text Link to item Cite

Safety monitoring of drugs receiving pediatric marketing exclusivity.

Journal article Pediatrics · September 2008 Featured Work OBJECTIVES: The Food and Drug Administration Modernization Act provided for an additional 6-month period of marketing exclusivity to companies that perform pediatric drug trials in response to a Food and Drug Administration-issued written request. Because ... Full text Link to item Cite

Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.

Journal article Clin Pharmacol Ther · September 2008 Featured Work Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension in children.(1) ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and cardiac hypertrophic properties of angiotensin II and the vasodilato ... Full text Link to item Cite

Safety of placebo controls in pediatric hypertension trials.

Journal article Hypertension · April 2008 Featured Work Many clinical trials, including those in pediatric populations, use a placebo arm for medical conditions for which there are readily available therapeutic interventions. Several short-term efficacy trials of antihypertensive medications performed in respon ... Full text Link to item Cite

Pediatric antihypertensive trial failures: analysis of end points and dose range.

Journal article Hypertension · April 2008 Featured Work Historically, drugs prescribed for children have not been studied in pediatric populations. Since 1997, however, a 6-month extension of marketing rights is granted if manufacturers conduct Food and Drug Administration-defined pediatric trials. In nearly ha ... Full text Link to item Cite

Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.

Journal article Circulation · January 29, 2008 Featured Work BACKGROUND: Infants and young children with certain types of heart disease are at increased risk for thromboses. Clopidogrel 75 mg/d is used in adults to prevent thrombotic events. The dose to achieve similar platelet inhibition in children is unknown. The ... Full text Link to item Cite

Delayed diagnosis of Kawasaki disease: what are the risk factors?

Journal article Pediatrics · December 2007 Featured Work OBJECTIVE: Because late diagnosis of Kawasaki disease increases the risk for coronary artery abnormalities, we explored the prevalence of and possible risk factors for delayed diagnosis by using the database of the Pediatric Heart Network trial of corticos ... Full text Link to item Cite

Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?

Journal article Circulation · July 17, 2007 Featured Work BACKGROUND: Aspirin (ASA) often is used to prevent thrombosis in infants with congenital heart disease after placement of a systemic-to-pulmonary artery shunt, but its effect on outcomes is unknown. METHODS AND RESULTS: The present multicenter study prospe ... Full text Link to item Cite

Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements.

Journal article Circulation · July 10, 2007 Featured Work BACKGROUND: Most studies of coronary artery involvement and associated risk factors in Kawasaki disease have used the Japanese Ministry of Health dichotomous criteria. Analysis of serial normalized artery measurements may reveal a broader continuous spectr ... Full text Link to item Cite

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Journal article N Engl J Med · February 15, 2007 Featured Work BACKGROUND: Treatment of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary-artery abnormalities and systemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities develop ... Full text Link to item Cite

Economic return of clinical trials performed under the pediatric exclusivity program.

Journal article JAMA · February 7, 2007 Featured Work CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric trials. The program has been pra ... Full text Open Access Link to item Cite

Peer-reviewed publication of clinical trials completed for pediatric exclusivity.

Journal article JAMA · September 13, 2006 Featured Work CONTEXT: Much of pediatric drug use is off-label because appropriate pediatric studies have not been conducted and the drugs have not been labeled by the US Food and Drug Administration (FDA) for use in children. In 1997, Congress authorized the FDA to gra ... Full text Link to item Cite

The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass.

Journal article Expert Rev Cardiovasc Ther · September 2006 Featured Work Cardiopulmonary bypass (CPB) for cardiac surgery or lung transplantation initiates a systemic inflammatory response characterized by increased vascular permeability, generalized edema, abnormal lung function and oxygenation and impaired ventricular functio ... Full text Link to item Cite

Racial differences are seen in blood pressure response to fosinopril in hypertensive children.

Journal article Am Heart J · August 2006 Featured Work BACKGROUND: Few antihypertensive therapies have been systematically studied in children and dosages for many agents are either extrapolated from adult studies or obtained from small homogenous pediatric populations. It is well established that adult patien ... Full text Link to item Cite

Electrocardiographic response to enzyme replacement therapy for Pompe disease.

Journal article Genet Med · May 2006 Featured Work PURPOSE: Electrocardiogram (ECG) abnormalities are universal in infantile Pompe disease or glycogen storage disease type II, a fatal genetic muscle disorder caused by deficiency of acid alpha-glucosidase (GAA). Hallmarks of this disease include a shortened ... Full text Link to item Cite

Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.

Journal article Genet Med · May 2006 Featured Work PURPOSE: Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase. Trials with recombinant human acid alpha-glucosidase enzyme replacement therapy (ERT) show a decrease in left ventricular mass and improved function. We evaluated ... Full text Link to item Cite

Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure.

Journal article Circulation · February 28, 2006 Featured Work BACKGROUND: After the Fontan procedure, patients are at risk for suboptimal health status related to their complex healthcare experience, physiological limitations, medical complications, and guarded long-term prognosis. METHODS AND RESULTS: In the Pediatr ... Full text Link to item Cite

Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia.

Journal article Pediatrics · January 2005 Featured Work PURPOSE: The prevalence of infective endocarditis (IE) among children with Staphylococcus aureus bacteremia (SAB) is unknown. The objective of this study was to determine prospectively the prevalence of IE among pediatric patients with SAB in a large terti ... Full text Link to item Cite

Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?

Journal article Hypertension · September 2004 Featured Work We evaluated the efficacy, safety, and dose-response relationship of fosinopril in children aged 6 to 16 years with hypertension or high-normal blood pressure with an associated medical condition requiring treatment. The study was a prospective, double-bli ... Full text Link to item Cite

Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.

Journal article Am Heart J · January 2004 Featured Work BACKGROUND: Increase in vascular permeability and multiorgan dysfunction after cardiopulmonary bypass (CPB) are barriers to successful cardiac surgery in infants. Complement inhibition with TP10, a C3/C5 convertase inhibitor (AVANT Immunotherapeutics, Need ... Full text Link to item Cite

Oral antihypertensive trial design and analysis under the pediatric exclusivity provision.

Journal article Am Heart J · October 2002 Featured Work BACKGROUND: The Best Pharmaceuticals for Children Act provides a 6-year extension to the economic incentives offered to drug manufacturers under the Pediatric Exclusivity Provision, for providing requested information on drugs used in children, which inclu ... Full text Link to item Cite

Real-time transmission of pediatric echocardiograms using a single ISDN line.

Journal article Comput Biol Med · September 2002 Featured Work We tested the adequacy of a videoconferencing system using a single integrated systems digital network (ISDN) line (128 kilobits per second) for the remote diagnosis of children with suspected congenital heart disease (CHD). Real-time echocardiogram interp ... Full text Link to item Cite

Bacterial endocarditis in infants and children.

Journal article Pediatr Infect Dis J · August 2001 Featured Work Full text Link to item Cite

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Journal article Clin Infect Dis · April 2000 Featured Work Although the sensitivity and specificity of the Duke criteria for the diagnosis of infective endocarditis (IE) have been validated by investigators from Europe and the United States, several shortcomings of this schema remain. The Duke IE database contains ... Full text Link to item Cite